(Q36498807)

14 August 2017

1 reference

title

Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation (English)

1 reference

14 August 2017

1 reference

Hitoshi Kiyoi

1

1 reference

14 August 2017

Tomoki Naoe

series ordinal

2

1 reference

14 August 2017

publication date

1 May 2006

1 reference

International Journal of Hematology

14 August 2017

published in

1 reference

14 August 2017

volume

83

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

301-308

1 reference

The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion

14 August 2017

cites work

1 reference

12 December 2020

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

1 reference

12 December 2020

Nucleolar protein B23 has molecular chaperone activities

1 reference

12 December 2020

Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response.

1 reference

12 December 2020

Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs

1 reference

12 December 2020

A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations

1 reference

12 December 2020

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

1 reference

12 December 2020

The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro

1 reference

12 December 2020

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells

1 reference

12 December 2020

Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells

1 reference

12 December 2020

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

12 December 2020

Clinical significance of FLT3 in leukemia

1 reference

12 December 2020

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

12 December 2020

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

1 reference

12 December 2020

Expression of the FLT3 gene in human leukemia-lymphoma cell lines

1 reference

12 December 2020

Nucleophosmin regulates the stability and transcriptional activity of p53

1 reference

12 December 2020

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

1 reference

12 December 2020

Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan

1 reference

12 December 2020

c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities

1 reference

12 December 2020

FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress

1 reference

12 December 2020

FLT3 tyrosine kinase inhibitors

1 reference

12 December 2020

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

1 reference

12 December 2020

Core-binding factors in haematopoiesis and leukaemia

1 reference

12 December 2020

Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells

1 reference

12 December 2020

In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

1 reference

12 December 2020

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia

1 reference

12 December 2020

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

1 reference

12 December 2020

FLT3: ITDoes matter in leukemia

1 reference

12 December 2020

Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group

1 reference

12 December 2020

Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia

1 reference

12 December 2020

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

12 December 2020

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

1 reference

12 December 2020

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

1 reference

12 December 2020

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

1 reference

12 December 2020

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

12 December 2020

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

12 December 2020

NPM mutations in acute myelogenous leukemia

1 reference

12 December 2020

Internal tandem duplication of the flt3 gene found in acute myeloid leukemia

1 reference

12 December 2020

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

1 reference

12 December 2020

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

12 December 2020

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

12 December 2020

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

1 reference

12 December 2020

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

12 December 2020

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family

1 reference

12 December 2020

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

1 reference

12 December 2020

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

12 December 2020

The role of FLT3 in haematopoietic malignancies

1 reference

12 December 2020

FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia.

1 reference

12 December 2020

Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines

1 reference

12 December 2020

Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells

1 reference

12 December 2020

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

1 reference

12 December 2020

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

1 reference

12 December 2020

A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia

1 reference

12 December 2020

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells

1 reference

12 December 2020

FLT3 in human hematologic malignancies

1 reference

12 December 2020

Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia

1 reference

12 December 2020

Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells

1 reference

12 December 2020

A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity

1 reference

12 December 2020

Biology of flt3 ligand and receptor

1 reference

12 December 2020

Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children

1 reference

12 December 2020

Flt3 mutations and leukaemia

1 reference

12 December 2020

Switching signals on or off by receptor dimerization

1 reference

12 December 2020

FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance

1 reference

12 December 2020

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy

1 reference

12 December 2020

Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia

1 reference

12 December 2020

Major nucleolar proteins shuttle between nucleus and cytoplasm

1 reference

12 December 2020

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)

1 reference

12 December 2020

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

1 reference

12 December 2020

Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth

1 reference

12 December 2020

Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family

1 reference

12 December 2020

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

12 December 2020

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

1 reference

12 December 2020

Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene

1 reference

12 December 2020

Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation

1 reference

12 December 2020

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

1 reference

12 December 2020

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

1 reference

12 December 2020

Expression and Signal Transduction of the FLT3 Tyrosine Kinase Receptor

1 reference

12 December 2020

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

1 reference

12 December 2020

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

12 December 2020

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

1 reference

12 December 2020

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

1 reference

12 December 2020

KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication

1 reference

12 December 2020

Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia

1 reference

12 December 2020

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia

1 reference

12 December 2020

Genomic structure of human FLT3: implications for mutational analysis

1 reference

12 December 2020

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression

1 reference

12 December 2020

Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells

1 reference

12 December 2020

The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1.

1 reference

12 December 2020

FLT3 mutations in acute myeloid leukemia

1 reference

12 December 2020

Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia

1 reference

12 December 2020

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

12 December 2020

Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene

1 reference

12 December 2020

Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children

1 reference

12 December 2020

Normal and oncogenic FLT3

1 reference

12 December 2020

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

12 December 2020

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

12 December 2020

Identifiers

DOI

10.1532/IJH97.06071

1 reference

Dimensions Publication ID

14 August 2017

1039928056

0 references

1 reference